dijous, 17 d’abril del 2014

Mainstay Medical readies European IPO




Mainstay Medical looks to raise up to $42 million with an initial public offering on the EuroNext stock exchange.





Mainstay Medical readies European IPO

Mainstay Medical is preparing an initial public offering on the EuroNext stock exchange that could be worth up to $42 million, according to a regulatory filing.


Mainstay, which last month launched a new clinical trial of its ReActiv8 implantable neurostimulator for chronic lower back pain, said it plans to offer some 1.1 million shares at €20-€27 per share, or about $27.77 to $37.50 per share.




read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1mhl0wI

Cap comentari:

Publica un comentari a l'entrada